JOSÉ MANUEL CALDERÓN MONTAÑO

Dr. JOSÉ MANUEL CALDERÓN MONTAÑO

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2010 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
EBEstefanía Burgos
Estefanía Burgos
JMJOSÉ MANUEL CALDERÓN MONTAÑO
JOSÉ MANUEL CALDERÓN MONTAÑO
JSJavier Salvador
Javier Salvador
ARAntonio Robles
Antonio Robles
MLMiguel Lopez-Lazaro
Miguel Lopez-Lazaro
Click on the article title to read more.

16 November 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
JCJordi Carreras-Puigvert
Jordi Carreras-Puigvert
MZMarinka Zitnik
Marinka Zitnik
AJAnn-Sofie Jemth
Ann-Sofie Jemth
MCMegan Carter
Megan Carter
JUJudith E. Unterlass
Judith E. Unterlass
THThomas Helleday
Thomas Helleday
The NUDIX enzymes are involved in cellular metabolism and homeostasis, as well as mRNA processing. Although highly conserved throughout all organisms, their biological roles and biochemical redundancies remain largely unclear. To address this, we globally resolve their individual properties and inter-relationships. We purify 18 of the human NUDIX proteins and screen 52 substrates, providing a substrate redundancy map. Using crystal structures, we generate sequence alignment analyses revealing four major structural classes. To a certain extent, their substrate preference redundancies correlate with structural classes, thus linking structure and activity relationships. To elucidate interdependence among the NUDIX hydrolases, we pairwise deplete them generating an epistatic interaction map, evaluate cell cycle perturbations upon knockdown in normal and cancer cells, and analyse their protein and mRNA expression in normal and cancer tissues. Using a novel FUSION algorithm, we integrate all data creating a comprehensive NUDIX enzyme profile map, which will prove fundamental to understanding their biological functionality.

1 June 2012 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
CCCarmen Martin Cordero
Carmen Martin Cordero
Antonio J. León-GonzálezAntonio J. León-González
Antonio J. León-González
JMJOSÉ MANUEL CALDERÓN MONTAÑO
JOSÉ MANUEL CALDERÓN MONTAÑO
EBEstefanía Burgos
Estefanía Burgos
MLMiguel Lopez-Lazaro
Miguel Lopez-Lazaro
Cancer cells produce high levels of reactive oxygen species (ROS) that lead to a state of increased basal oxidative stress. Since this state of oxidative stress makes cancer cells vulnerable to agents that further augment ROS levels, the use of pro-oxidant agents is emerging as an exciting strategy to selectively target tumor cells. Natural products have provided a significant contribution to the development of several drugs currently used in cancer chemotherapy. Although many natural products are known to affect the redox state of the cell, most studies on these compounds have focused on their antioxidant activity instead of on their pro-oxidant properties. This article provides an overview of natural products with pro-oxidant and anticancer activities, with special focus on plant secondary metabolites, and discusses their possible use as cancer chemotherapeutic agents.

9 January 2017 in Nature Medicine
Verified
Journal Article
Closed access
Nikolas HeroldNikolas Herold
Nikolas Herold
SRSean Rudd
Sean Rudd
LLLinda Ljungblad
Linda Ljungblad
KSKumar Sanjiv
Kumar Sanjiv
IMIda Hed Myrberg
Ida Hed Myrberg
TSTorsten Schaller
Torsten Schaller

8 May 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
JMJOSÉ MANUEL CALDERÓN MONTAÑO
JOSÉ MANUEL CALDERÓN MONTAÑO
EBEstefanía Burgos
Estefanía Burgos
MOManuel Luís Orta
Manuel Luís Orta
DMDolores Maldonado-Navas
Dolores Maldonado-Navas
Irene García DomínguezIrene García Domínguez
Irene García Domínguez
MLMiguel Lopez-Lazaro
Miguel Lopez-Lazaro
Cardiac glycosides, also known as cardiotonic steroids, are a group of natural products that share a steroid-like structure with an unsaturated lactone ring and the ability to induce cardiotonic effects mediated by a selective inhibition of the Na+/K+-ATPase. Cardiac glycosides have been used for many years in the treatment of cardiac congestion and some types of cardiac arrhythmias. Recent data suggest that cardiac glycosides may also be useful in the treatment of cancer. These compounds typically inhibit cancer cell proliferation at nanomolar concentrations, and recent high-throughput screenings of drug libraries have therefore identified cardiac glycosides as potent inhibitors of cancer cell growth. Cardiac glycosides can also block tumor growth in rodent models, which further supports the idea that they have potential for cancer therapy. Evidence also suggests, however, that cardiac glycosides may not inhibit cancer cell proliferation selectively and the potent inhibition of tumor growth induced by cardiac glycosides in mice xenografted with human cancer cells is probably an experimental artifact caused by their ability to selectively kill human cells versus rodent cells. This paper reviews such evidence and discusses experimental approaches that could be used to reveal the cancer therapeutic potential of cardiac glycosides in preclinical studies.

22 April 2013 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
MOManuel Luís Orta
Manuel Luís Orta
JMJOSÉ MANUEL CALDERÓN MONTAÑO
JOSÉ MANUEL CALDERÓN MONTAÑO
IDInmaculada Domínguez
Inmaculada Domínguez
NPNuria Pastor
Nuria Pastor
EBEstefanía Burgos
Estefanía Burgos
THThomas Helleday
Thomas Helleday
5-Aza-2′-deoxycytidine (5-azadC) is a DNA methyltransferase (DNMT) inhibitor increasingly used in treatments of hematological diseases and works by being incorporated into DNA and trapping DNMT. It is unclear what DNA lesions are caused by 5-azadC and if such are substrates for DNA repair. Here, we identify that 5-azadC induces DNA damage as measured by γ-H2AX and 53BP1 foci. Furthermore, 5-azadC induces radial chromosomes and chromatid breaks that depend on active replication, which altogether suggest that trapped DNMT collapses oncoming replication forks into double-strand breaks. We demonstrate that RAD51-mediated homologous recombination (HR) is activated to repair 5-azadC collapsed replication forks. Fanconi anemia (FA) is a rare autosomal recessive disorder, and deaths are often associated with leukemia. Here, we show that FANCG -deficient cells fail to trigger HR-mediated repair of 5-azadC-induced lesions, leading to accumulation of chromatid breaks and inter-chromosomal radial fusions as well as hypersensitivity to the cytotoxic effects of 5-azadC. These data demonstrate that the FA pathway is important to protect from 5-azadC-induced toxicity. Altogether, our data demonstrate that cytotoxicity of the epigenetic drug 5-azadC can, at least in part, be explained by collapsed replication forks requiring FA-mediated HR for repair.